Completed PHASE4 INTERVENTIONAL 2-arm NCT01884350

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (AEGEAN)

Sponsor: Bristol-Myers Squibb

Conditions Non-valvular Atrial Fibrillation

Interventions Apixaban

Updated 8 times since 2017 Last updated: Jul 10, 2019 Started: Oct 15, 2013 Primary completion: Jan 20, 2016 Completion: Jan 20, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01884350, this PHASE4 trial focuses on Non-valvular Atrial Fibrillation and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Sep 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbeville, France , Airdrie, United Kingdom , Aix-en-Provence, France , Aldaia, Spain , Alicante, Spain , Antwerp, Belgium , Arezzo, Italy , Arlon, Belgium , Ashford, United Kingdom , Augsburg, Germany and 175 more locations